Table 1

Economic data on closed system drug transfer devices from studies that reported actual costs

ReferenceCSTDCostsCost savingsCHEERS criteriaLimitations
TypeValuesTypeValues
Ozyaman (2016)
Turkey19
PhaSeal
(compared with conventional system)
Not evaluatedNot evaluatedExtension of
BUD
€36 137/
3 months
NAAcquisition costs not evaluated. Partial data reported (as a poster).
Kicenuik et al (2017)
USA23
Equashield
PhaSeal
(compared with conventional system)
Acquisition costs, administration timeEquashield:
US$15.73/dose
24 s/dose
PhaSeal:
US$24.09/dose
29.1 s/dose
Conventional:
26.9 s/dose
Not evaluatedNot evaluated12/24Phaseal sold by the unit and Equashield sold in bulk.
Simulated administrations.
Acquisition costs not evaluated for conventional system.
Conflicts of interest:
CSTDs provided free of charge by the manufacturers.
  • BUD, beyond-use date; CHEERS, Consolidated Health Economic Evaluation Reporting Standards; CSTD, closed system transfer device; NA, not applicable.